Suberanilohydroxamic acid (SAHA) is a histone deacetylase (HDAC) inhibitor which has been studied in recent clinical trials of pediatric and adult high-grade glioma patients [9, 10]. This evidence concerns the gene HDAC9 and central nervous system cancer.